Rexahn Pharma hires investment banker Frederick Frank as an independent consultant

Rexahn Pharma hires investment banker Frederick Frank as an independent consultant
Tuesday, June 08, 2010 Rexahn Pharmaceuticals Inc (AMEX:RNN) said it hired Frederick Frank, the current vice-chairman of Peter J. Solomon Co (PJSC), to advise on a range of corporate activities. As an independent consultant, Frank is expected to help Rexahn build its assets and drive shareholder value.

"Rexahn is in a great position with a strong pipeline, best-in-class products, and the positive Phase II clinical results of Serdaxin and Zoraxel. I am looking forward to helping the company build value for these assets," Frederick Frank said.

The company highlighted Frank's extensive experience in investment banking, noted his specific experience in relation to the pharmaceutical, biotechnology, healthcare services, medical device and nutraceutical industries. "He has been involved in hundreds of financings, strategic alliances and merger and acquisition transactions in the global healthcare industry", Rexahn stated.

Proactiveinvestors recommends
Biocompatibles' drug eluting beads for cancer continue to deliver solid platform for growthEco Animal Health: helping the meat industry to stay in good shapeOxford Nutrascience - could be worth a chewRexahn chairman and CEO Dr. Chang Ahn commented: "His expertise in global healthcare and 50 years of banking experience focused in biotechnology will be a great asset to the company."

Rexahn is a clinical stage biopharmaceutical company, commercializing oncology and central nervous system (CNS) therapeutics. Rexahn's core scientific expertise is in signal transduction; this has produced a drug portfolio with significant potential clinical value.

The company is working on a variety of therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs.

Rexahn currently has three drug candidates in Phase II clinical trials, Archexin, Serdaxin, and Zoraxel - all potential best in class therapeutics - and a pipeline of preclinical compounds in development to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms.

One of the company's most advanced development products is Serdaxin, which according to Rexahn prevents neuronal death which is a disease mechanism implicated in many brain disorders from depression to Parkinson's and Alzheimer's diseases. The treatment protects dopamine-releasing neurons from environmental damage. Serdaxin directly targets the disease mechanism by slowing or halting the progression of the disease, Rexahn state.

The company has multiple clinical programs planned for investigating Serdaxin in the treatment of anxiety disorders, Parkinson's disease, Alzheimer's disease and neurodegenerative illnesses, neuro-protection and bio-defense

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.